Abstrakt

ALLHAT: implications in the diabetic population

Samy I McFarlane

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is the largest hypertension study ever conducted. It included a large number of diabetic patients, representing nearly a third of its entire cohort of 42,448 participants. Furthermore, the study showed a significant increase in the number of incident diabetes cases with the use of chlorothalidone throughout the trial. In this report we discuss the major ALLHAT results with emphasis on the diabetic population, a particularly high-risk group for cardiovascular events, the primary outcome for the trial.